VYNE Therapeutics Inc. (VYNE)

Market Cap	25.21M
Revenue (ttm)	501,000
Net Income (ttm)	-39.83M
Shares Out	14.83M
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	307,416
Open	1.810
Previous Close	1.780
Day's Range	1.620 - 1.830
52-Week Range	1.570 - 4.300
Beta	1.25
Analysts	Strong Buy
Price Target	6.88 (+304.71%)
Earnings Date	Mar 6, 2025

About VYNE

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of chronic inflammatory and immune-mediated conditions. Its lead program, repibresib gel (VYN201), is a topically administered small molecule pan bromodomain (BD) extra-terminal (BET) inhibitor soft drug that address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. The company also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 25, 2018
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: VYNE
• Website: https://vynetherapeutics.com

Financial Performance

In 2024, VYNE Therapeutics's revenue was $501,000, an increase of 18.16% compared to the previous year's $424,000. Losses were -$39.83 million, 39.3% more than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for VYNE stock is "Strong Buy." The 12-month stock price forecast is $6.88, which is an increase of 304.71% from the latest price.

Price Target

$6.88

(304.71% upside)

Analyst Consensus: Strong Buy